Manoj Tyagi
Head of Bioinformatics Unit
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (1)
Purpose: Despite promising preclinical studies, toxicities have precluded combinations of chemotherapy and DNA damage response (DDR) inhibitors. We hypothesized that tumor-targeted chemotherapy delivery might enable clinical translation of such combinations. Patients and Methods: In a phase I trial, we combined sacituzumab govitecan, antibody-drug conjugate (ADC) that delivers topoisomerase-1 inhibitor SN-38 to tumors expressing Trop-2, with ataxia telangiectasia and Rad3-related (ATR) inhibitor berzosertib. Twelve patients were enrolled across three dose levels. Results: Treatment was well tolerated, with improved safety over conventional chemotherapy-based combinations, allowing escalation to the highest dose. No dose-limiting toxicities or clinically relevant ≥ grade 4 adverse events occurred. Tumor regressions were observed in two patients with neuroendocrine prostate cancer and a patient with small cell lung cancer transformed from EGFR-mutant non-small cell lung cancer. Conclusions: ADC-based delivery of cytotoxic payloads represents a new paradigm to increase efficacy of DDR inhibitors.
Year:
2024
Collaborators (5)
Parth Anil Desai
Assistant Professor/Clinical Investigator
Fox Chase Cancer Center
Christopher William Schultz
Assistant Professor
Temple University
Liqiang Xi
Staff Scientist
National Institutes of Health
SHUBHANK GOYAL
The University of Texas Rio Grande Valley
William D Figg
Senior Investigator, Lab Chief, Associate Director
National Institutes of Health
Make your next move.
Prepare your application
Review drafts before you send them.